Ocular Therapeutix, Inc. (OCUL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
OCUL Revenue Growth
Revenue Breakdown (FY 2025)
OCUL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
OCUL Revenue Analysis (2014–2025)
As of May 8, 2026, Ocular Therapeutix, Inc. (OCUL) generated trailing twelve-month (TTM) revenue of $52.0 million, reflecting modest growth of +0.8% year-over-year. The most recent quarter (Q1 2026) recorded $10.8 million in revenue, down 18.6% sequentially.
Looking at the longer-term picture, OCUL's 5-year compound annual growth rate (CAGR) stands at +24.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $63.7 million in 2024.
Revenue diversification analysis shows OCUL's business is primarily driven by Product (100%), and Collaboration revenue (0%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVCR (+8.5% YoY), and SGHT (+1.8% YoY), OCUL has underperformed the peer group in terms of revenue growth. Compare OCUL vs NVCR →
OCUL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| OCULCurrent | $52M | +0.8% | +24.4% | -521.0% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 SGHT | $77M | +1.8% | +22.9% | -48.0% |
OCUL Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $51.8M | -18.7% | $45.2M | 87.3% | $-270,017,000 | -521.0% |
| 2024 | $63.7M | +9.0% | $58.1M | 91.2% | $-171,781,000 | -269.6% |
| 2023 | $58.4M | +13.5% | $53.2M | 91.0% | $-82,382,000 | -141.0% |
| 2022 | $51.5M | +18.3% | $47.0M | 91.2% | $-78,654,000 | -152.7% |
| 2021 | $43.5M | +150.1% | $39.1M | 89.9% | $-78,037,000 | -179.3% |
| 2020 | $17.4M | +311.7% | $15.3M | 88.0% | $-62,847,000 | -361.1% |
| 2019 | $4.2M | +112.4% | $1.9M | 45.0% | $-85,802,000 | -2029.9% |
| 2018 | $2.0M | +3.5% | $1.5M | 76.6% | $-59,118,000 | -2970.8% |
| 2017 | $1.9M | +1.9% | $1.5M | 76.2% | $-61,923,000 | -3220.1% |
| 2016 | $1.9M | +7.8% | $1.4M | 76.5% | $-43,326,000 | -2296.0% |
See OCUL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OCUL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OCUL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOCUL — Frequently Asked Questions
Quick answers to the most common questions about buying OCUL stock.
Is OCUL's revenue growth accelerating or slowing?
OCUL revenue growth slowed to +0.8%, below the 5-year CAGR of +24.4%. TTM revenue is $52M. The deceleration marks a shift from historical growth rates.
What is OCUL's long-term revenue growth rate?
Ocular Therapeutix, Inc.'s 5-year revenue CAGR of +24.4% reflects the variable expansion pattern. Current YoY growth of +0.8% is near this long-term average.
How is OCUL's revenue distributed by segment?
OCUL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.